InvenTrust Properties Corp. Common Stock IVT 深 沪
已收盘 10-10 16:00:00 美东时间
27.24
-0.290
-1.05%
华盛通- 最 高27.78
- 今 开27.68
- 成交量 95.55万股
- 最 低 27.08
- 昨 收 27.53
- 总市值 21.14亿
- 52周最高 30.7107
- 市盈率 静 141.65
- 换手率 0.00%
- 52周最低 24.7346
- 委 比 94.71%
- 总股本 7760.64万
- 历史最高 30.7107
- 量 比 1.50
- 振 幅 2.54%
- 历史最低 18.1346
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
Ocular Therapeutix (NASDAQ:OCUL) has been analyzed by 4 analysts in the last th...
10-01 22:02
Alvotech's Commercialization Partner In Japan, Fuji Pharma, Receives Marketing Approval For Three New Biosimilars From Japanese Ministry Of Health, Labor And Welfare
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma
09-19 19:47
InvenTrust Properties declares $0.2377 dividend
InvenTrust Properties (NYSE:IVT) declared $0.2377/share quarterly dividend, in line with previous. Forward yield 3.2% Payable Oct. 15; for shareholders of record Sept. 30; ex-div Sept. 30. See IVT Div...
09-17 04:06
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Ladenburg Thalmann Initiates Coverage On InvenTrust Properties with Neutral Rating, Announces Price Target of $31
Ladenburg Thalmann analyst Floris Van Dijkum initiates coverage on InvenTrust Properties (NYSE:IVT) with a Neutral rating and announces Price Target of $31.
09-09 19:45
Wells Fargo Maintains Overweight on InvenTrust Properties, Raises Price Target to $34
Wells Fargo analyst Dori Kesten maintains InvenTrust Properties (NYSE:IVT) with a Overweight and raises the price target from $32 to $34.
08-27 21:39
眼科领域突破！复宏汉霖贝伐珠单抗 HLX04-O眼科适应症国内上市申请获受理
内容来源：复宏汉霖 2025年8月13日，复宏汉霖宣布，公司与亿胜生物合作开发的重组抗血管内皮生长因子(Vascular endothelial growth...
08-14 17:45
亿胜生物：重组抗VEGF眼内注射液HLX04-O上市注册申请获NMPA受理
8月13日，亿胜生物科技有限公司（1061.HK）宣布，集团针对重组抗VEGF眼内注射液EB12-20145P（HLX04-O）的上市注册申请已被中国国家药品监督管理局药品审评中心受理。该产品由集团与复宏汉霖（股票代码：2696.HK）合作开发，用于治疗湿性年龄相关性黄斑变性。
08-13 20:45
What's Next: Ocular Therapeutix's Earnings Preview
Ocular Therapeutix (NASDAQ:OCUL) will release its quarterly earnings report on ...
08-05 04:04
InvenTrust Properties Highlights Q2 2025 Performance and Strategy
InvenTrust Properties ( ($IVT) ) has provided an update. On July 29, 2025, Inve...
07-30 05:51
